- Home
- CSTL vs HYMC Comparison
CSTL vs HYMC Comparison
Compare CSTL & HYMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- HYMC
- Stock Information
- Founded
- CSTL 2007
- HYMC N/A
- Country
- CSTL United States
- HYMC United States
- Employees
- CSTL N/A
- HYMC N/A
- Industry
- CSTL Medical Specialities
- HYMC Precious Metals
- Sector
- CSTL Health Care
- HYMC Basic Materials
- Exchange
- CSTL Nasdaq
- HYMC Nasdaq
- Market Cap
- CSTL 661.7M
- HYMC 648.5M
- IPO Year
- CSTL 2019
- HYMC N/A
- Fundamental
- Price
- CSTL $33.02
- HYMC $7.60
- Analyst Decision
- CSTL Strong Buy
- HYMC
- Analyst Count
- CSTL 6
- HYMC 0
- Target Price
- CSTL $38.67
- HYMC N/A
- AVG Volume (30 Days)
- CSTL 421.5K
- HYMC 1.6M
- Earning Date
- CSTL 11-03-2025
- HYMC 10-28-2025
- Dividend Yield
- CSTL N/A
- HYMC N/A
- EPS Growth
- CSTL N/A
- HYMC N/A
- EPS
- CSTL N/A
- HYMC N/A
- Revenue
- CSTL $343,530,000.00
- HYMC N/A
- Revenue This Year
- CSTL N/A
- HYMC N/A
- Revenue Next Year
- CSTL N/A
- HYMC N/A
- P/E Ratio
- CSTL N/A
- HYMC N/A
- Revenue Growth
- CSTL 10.15
- HYMC N/A
- 52 Week Low
- CSTL $14.59
- HYMC $1.99
- 52 Week High
- CSTL $34.64
- HYMC $9.75
- Technical
- Relative Strength Index (RSI)
- CSTL 81.56
- HYMC 52.65
- Support Level
- CSTL $23.31
- HYMC $7.21
- Resistance Level
- CSTL $34.36
- HYMC $7.84
- Average True Range (ATR)
- CSTL 1.50
- HYMC 0.64
- MACD
- CSTL 1.08
- HYMC -0.12
- Stochastic Oscillator
- CSTL 89.19
- HYMC 60.85
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About HYMC Hycroft Mining Holding Corporation
Hycroft Mining Holding Corp is a gold and silver producer. Its operating mine, the Hycroft Mine, is an open-pit heap leach operation located approximately fifty four miles west of Winnemucca, Nevada.